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Preface
This monograph is written for healthcare workers in any setting who are faced with
the complex care for patients with tuberculosis. Prevention, diagnosis and treatment
of tuberculosis are fraught with challenges that are often reflective of problems in
society as a whole. Significant progress has been made since the millennium;
Global TB incidence has been reduced, access to rapid molecular diagnosis for both
TB and drug resistance has been scaled up, and two new TB drugs have been
approved in Europe and the USA. However, major political and socio-economic
obstacles remain in the translation of these and other advances into equitable TB
healthcare access for all. Access to information on developments in TB care is one
such barrier, and by summarizing the most recent advances in disease epidemiol-
ogy, scientific achievements in treatment and diagnosis and current recommenda-
tions for all forms of tuberculosis, we hope to improve the dissemination of access
to the latest evidence base for the care of individuals with tuberculosis.
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Abstract This chapter will describe the pathogen which causes tuberculosis:
Mycobacterium tuberculosis. It will give an overview of the historical context, the
molecular and clinical epidemiology of tuberculosis in adults and children globally
and describes how other epidemics, such as HIV and diabetes, influence disease
control. It also summarizes the current efforts of the WHO to curtail the pandemic.
Keywords Tuberculosis  Mycobacterium tuberculosis  Lineage  Virulence 
Drug-resistance  Epidemiology  HIV  Prognosis
1.1 Tuberculosis in History
Tuberculosis (TB) has caused more deaths through the last 200 years than any other
infectious disease, and has been with us since ancient times (Paulson 2013).
Evidence of tuberculosis has been found in 9,000 year old mummies. There are
conflicting theories of the timing of the emergence of Mycobacterium tuberculosis
(M.tuberculosis) as a human pathogen with two recent theories proposing
70,000 years ago (Comas et al. 2013) or 6,000 years ago. The later study proposed
that seals first transmitted the disease to humans (Bos et al. 2014).
Tuberculosis (TB) is a chronic granulomatous disease caused by the bacterium
M. tuberculosis, and more rarely, other species of the Mycobacterium tuberculosis
complex including Mycobacterium bovis and Mycobacterium africanum. The term
“tubercle” in the context of consumptive (“wasting”) disease was first coined by
Fransiscus de la Boë (also known as Sylvius of Leyden), a Dutch anatomist in the
17th century. He found tubercles (from: tuberculum, “small lump” in Latin) in the
lungs of most consumptives. Before the discovery of the pathogen in 1882 by
Robert Koch, the spectrum of diseases caused by the mycobacteria were known by
many names including: consumption, phtisis (from Greek “phtinein” to waste
away), scrofula (swelling of lymphnodes, especially in the neck), Pott’s disease
(tuberculous spondylitis, named after a British orthopedic surgeon Percivall Pott, in
© The Author(s) 2015
D. Heemskerk et al., Tuberculosis in Adults and Children,
SpringerBriefs in Public Health, DOI 10.1007/978-3-319-19132-4_1
1
the 18th century, but found in Egyptian mummies and art as early as 1000 BC),
yaksma (from Sanskrit: gradual destruction) and shaky oncay (Incan), balasa
(Hindu: swelling). The European epidemic in the 17th century was known as “the
white plague” (Fig. 1.1).
1.2 Pathogen
TB is caused by bacteria of the Mycobacterium tuberculosis complex, mostly
M.tuberculosis, but rarely also M.canetti, M.microti, M.africanum, and M.bovis
(de Jong et al. 2010). Mycobacteria are non-motile, non spore-forming, aerobic,
rod-shaped bacteria of 2–4 µm in length and possess a unique lipid-rich cell wall
which gives the ‘acid-fast’ property by which they are known (acid-fast bacilli, or
THE CAPTAIN OF ALL THESE MEN OF DEATH: 
Deaths from Infectious Diseases in last 200 years
Fig. 1.1 The burden of tuberculosis. From Paulson T. Nature, 2013. Reprinted with permission
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AFBs) and renders them resistant to many disinfectants and antibiotics. They can be
divided into slow growing or rapid growing species (Image 1.1).
M. tuberculosis is slow-growing, non-pigmented and appears as cream coloured
‘breadcrumbs’ on culture, often also described as ‘rough, tough and buff’ (Collins
1997) (Image 1.2). Other mycobacteria are variously described by the synonymous
terms non-tuberculous mycobacteria (NTM), mycobacteria other than tuberculosis
(MOTT) and atypical mycobacteria. NTM management is complex and poorly
standardized due to differences in disease presentation and available treatment
options. This book will focus on TB; for guidance on NTM management refer to the
American Thoracic Society (ATS) guidelines: http://www.thoracic.org/statements/
resources/mtpi/nontuberculous-mycobacterial-diseases.pdf. The only other major
human pathogen of the mycobacteria genus is M. leprae, which causes leprosy and is
not discussed further (White and Franco-Paredes 2015).
The whole genome ofM. tuberculosis (laboratory strain H37Rv) was sequenced in
1998 (Cole et al. 1998). Subsequent sequencing of clinical strains from around the
world has illuminated pathogen diversity, evolution and spread (Comas et al. 2013).
Six major geographic lineages of M. tuberculosis have been identified: the
Image 1.1 Transmission electron microscope image of Mycobacterium tuberculosis. The Black
arrow indicates the thick myolic acid layer. The n. indicates the nucleide (from Srinivasan et al.,
Arch Microbiol, 2014, reprinted with permission)
Image 1.2 Mycobacterium tuberculosis colonies on solid Lowenstein Jensen medium (courtesy
of Dr. Dang Thi Minh Ha)
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Euro-American, Indo-Oceanic, East-Asian (including Beijing strains), West-African
1 and 2, and East-African-Indian. Many studies have attempted to identify
lineage-specific differences in clinical virulence and/or transmissibility, but results
have been conflicting. These different findings may be the result of differences in the
particular strains used for comparison, variation in host genetics, environmental
influences or different study methodologies.
Some strains (e.g. Beijing and Haarlem strains) have been associated with
increased drug resistance. This may result from intrinsic factors such as increased
genetic mutation rates, intrinsic drug tolerance, lower fitness cost associated with
resistance-conferring mutations (Ford et al. 2013), or from environmental factors
that facilitated its emergence and spread. Current typing methods such as spoli-
gotyping, IS6110 restriction fragment length polymorphism (RFLP) and variable
number tandem repeat (VNTR) have value for outbreak investigations and studies
of population transmission, but do not offer any information to guide treatment.
Advances in the speed and cost of whole genome sequencing will soon supersede
other typing techniques and would be far more informative, facilitating detailed
transmission mapping and proving information on likely drug-resistance to guide
clinical management (Anderson et al. 2014; Comas et al. 2013; Barry et al. 2012;
Borrell and Gagneux 2009; Borrell et al. 2013; Cohen et al. 2011; Coll et al. 2013;
Steiner et al. 2014).
1.3 Epidemiology
Although TB is often thought of as a historical disease in the developed world, this is
not the case. Globally in 2012 there were an estimated 8.6 million new cases of
active TB and 1.3 million deaths; therefore there is one new TB case every 4 s and
more than two TB deaths every minute. Twenty-two high-burden countries account
for 80 % of all TB cases, with India and China alone contributing almost 40 % (26
and 12 % respectively). The TB incidence per 100,000 population varies dramati-
cally, from less than 10 per 100,000 in developed countries such as Japan, the United
States, Western Europe and Australia, to rates exceeding 1000 per 100,000 in South
Africa and Swaziland (WHO 2014). Overall, it is estimated that just 64 % of incident
TB cases were notified to National TB Programmes in 2013 (WHO 2014).
In high burden settings, TB has its peak incidence in early adulthood, affecting
the most economically productive age-groups. Whilst in low burden countries, TB
is more common in the elderly; also in immigrant populations and the socially
destitute. In the United States 63 % of the 9945 TB cases (a rate of 3.2 cases per
100,000 persons) reported in 2012 were among immigrants; with case rates 11
times higher than among US-born citizens (http://www.cdc.gov/tb/statistics/reports/
2012/default.htm). In a Dutch study on long-term travellers to TB endemic coun-
tries the overall TB was estimated to be 3.5 per 1000 person-months of travel
(Cobelens et al. 2000). TB notifications are usually higher among men than women
in a ratio of approximately 2:1. Despite this, TB is a leading non-obstetric cause of
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death in women from TB endemic areas (WHO 2002). Various theories have been
proposed to account for this difference including differences in smoking rates,
occupational lung damage, social networking patterns and immune function. It is
likely that the causes are multifactorial and include potential detection bias in
settings where women have greater difficulty in accessing health care.
Infection with human-immunodeficiency virus (HIV) greatly increases the
chances of an individual developing active TB following exposure, or of having
reactivation of latent disease, with the probability increasing as immunosuppression
advances (Lin and Flynn 2010). For an HIV uninfected individual with latent TB
there is a 10% lifetime risk of developing active TB disease, while for those with HIV
there is a 10 % annual risk (WHO 2008). 1.1 million (13 %) of the incident TB cases
in 2012 were in people living with HIV/AIDS and 75 % of these were in sub-Saharan
Africa. TB is the leading cause of death among HIV-infected patients, with an esti-
mated one in four HIV-related deaths attributed to TB (WHO 2008) (Fig. 1.2).
Young children with TB are generally less infectious and due to the difficulty of
confirming a TB diagnosis in this age group, data has not been systematically
collected on the TB disease burden suffered by children and many are treated without
notification. However, since 2010 countries have been encouraged to report age
disaggregated data to WHO for children less than 5 years and 5–14 years of age.
Despite being limited by poor case ascertainment and incomplete reporting, WHO
estimates that 530,000 children developed TB during 2012; resulting in 74,000
deaths among HIV-uninfected (and many more among HIV-infected) children
(WHO 2013). The contribution of TB to child mortality is undetermined, particularly
Fig. 1.2 Estimated TB incidence rates. Source WHO, reprinted with permission
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in TB endemic areas. More recent estimates are that*1 million incident cases occur
among children every year (Jenkins et al. 2014), while the contribution of TB to
under-5 mortality is likely to be underestimated in TB endemic areas, especially
among children dying from pneumonia, malnutrition and meningitis (Graham et al.
2014). Pooled analysis of autopsy studies identified TB in *10 % of 811 children
(both HIV-infected and -uninfected) who died from respiratory disease in five
African countries (Marais et al. 2014). Of the estimated 1.3 million deaths in children
attributed to pneumonia in 2011, most occurred among young children living in TB
endemic areas (Zar et al. 2013). Apart from its contribution to “pneumonia deaths”,
TB may also be the underlying cause in a substantial number of children dying from
meningitis, presumed sepsis, HIV/AIDS or severe malnutrition.
Smoking, diabetes and other co-morbidities increase susceptibility to active TB.
The increasing prevalence of diabetes, particularly in developing Asian countries
such as India and China has focused attention on the link between diabetes and TB
susceptibility and in 2011 WHO issued guidelines for the integrated management of
TB among diabetes patients (WHO 2011). It has been predicted that global diabetes
prevalence will increase by 69 % by 2030, with 80 % of prevalent cases in the
developing world (Shaw et al. 2009). Individuals living with diabetes have a 2–3
times higher risk of developing active TB; around 10 % of TB cases globally are now
linked to diabetes (WHO 2011). The Stop TB Strategy was launched in 2006 and now
aims to eliminate TB (defined as <1 case/million population) by 2050 (http://www.
who.int/tb/features_archive/global_plan_to_stop_tb/en/). Efforts towards elimina-
tion are challenged by the HIV pandemic and the increasing prevalence of drug
resistant strains of M. tuberculosis (Fig. 1.3).
Fig. 1.3 Percentage of new TB cases with MDR-TB. Source WHO, reprinted with permission
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1.4 Prognosis
TB is a curable disease. The fact that it remains the most pressing public health
problem for a significant proportion of the world, despite the availability of a cure
and knowledge on prevention of transmission shows how medicine can fail without
commitment at all levels of the community. The distribution of the TB pandemic
painfully demonstrates the inequalities in health care delivery globally. Over 95 %
of cases and deaths are in low and middle income countries. In general, prognosis
of outcome is dependent on a multitude of factors: host factors (genetic variance,
co-morbidities, HIV-coinfection, treatment adherence, access to healthcare) and
pathogen factors (pathogen virulence, drug-resistance) and the site of the infection
(pulmonary or extrapulmonary). The principle factors in a favourable outcome are
early recognition, drug susceptibility and appropriate treatment. Without treatment,
the case fatality for sputum culture positive (HIV negative) patients is estimated to
be 70 %, in contrast with sputum culture negative patients for whom it is estimated
to be 20 % (Tiemersma et al. 2011). The treatment success rate (either cured or
finished a full course of treatment) for newly diagnosed sputum positive TB patients
reported for the US in 2011 (according to WHO) was 78 %. For new smear
negative and extrapulmonary TB, treatment success rate is 85 % (http://www.who.
int/gho/tb/epidemic/treatment/en/).
TB is the most common cause of death among HIV patients, estimated to cause
26 % of AIDS related deaths. The treatment success rate globally for all new TB
patients without HIV was 87 %, in contrast with a 73 % success rate for new TB
patients with HIV (Getahun et al. 2010). The most lethal form of TB is TB men-
ingitis, which, when treated, has a mortality of approximately 25 % in HIV negative
patients and can exceed 60 % in HIV positive patients. Half of TB meningitis
survivors will suffer neurological sequelae (Thwaites et al. 2004; Torok et al. 2011).
Drug resistant TB carries a higher mortality than drug susceptible TB. Of the
34,000 MDR patients enrolled on treatment in 2010, only 48 % successfully
completed treatment and 15 % died. Among 795 XDR cases, mortality was
approximately 50 %.
The key to maintaining the momentum towards achieving the STOPTB target of
global TB eradication by 2050 will be sustained commitment from donors, gov-
ernments, national TB programmes, researchers and other stakeholders at all levels
of society.
Open Access This chapter is distributed under the terms of the Creative Commons Attribution
Noncommercial License, which permits any noncommercial use, distribution, and reproduction in




Abstract In this section the different phases of infection with Mycobacterium
tuberculosis will be reviewed. Starting from transmission by inhalation, to the
innate and adaptive immune response and the dual role of tuberculoma formation in
walling off infection, but also providing an advantageous environment for bacilli to
survive and multiply. Recent data has shown the role of Tumour Necrosis Factor
alpha (TNF-α) in tuberculoma maintenance and its genetic control is more complex
than previously thought. The role of vitamin D in susceptibility to tuberculosis also
an area which has seen a resurgence of interest and new evidence emerging that
targeted vitamin D therapy may have a role in improving TB outcomes.
Keywords Transmission  Innate immune response  Aadaptive immune
response  Tumor necrosis factor (TNF)  Tuberculoma  Granuloma  Vitamin D 
Susceptibility  Interferron gamma (IFN)
2.1 Transmission
Transmission of TB is by inhalation of infectious droplet nuclei containing viable
bacilli (aerosol spread). Mycobacteria-laden droplet nuclei are formed when a
patient with active pulmonary TB coughs and can remain suspended in the air for
several hours. Sneezing or singing may also expel bacilli. Factors influencing the
chance of transmission include the bacillary load of the source case (sputum
smear-positive or lung cavities on chest radiograph), as well as the proximity and
duration of exposure (Escombe et al. 2008). Transmission is dramatically and
rapidly reduced with effective treatment (Dharmadhikari et al. 2014). In general, the
risk of infection among household contacts of TB patients is *30 % (Singh et al.
2005) (Fig. 2.1).
For reasons not clearly understood, the majority of individuals infected with
M. tuberculosis (*90 %) do not develop disease. Following inhalation of
M. tuberculosis an individual may have one of the following outcomes: (1) fail to
© The Author(s) 2015
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register an infection, (2) become infected but then clear the infection, (3) success-
fully contain the infection but continue to harbour bacilli in the absence of
symptomatic disease (latent TB infection), or (4) develop progressive TB disease
(Saenz et al. 2013). It has been estimated that one-third of the world population
have latent TB infection and may be at risk to develop TB disease as they age, or
become immunocompromised in the future. The factors resulting in reactivation of
latent TB infection in the absence of overt immune suppression are not well
understood, but the huge reservoir of individuals with latent TB infection represents
a major barrier to TB elimination (Dye and Williams 2010).
Susceptibility to TB is influenced by environmental, host and pathogen factors.
Innate immune responses play a crucial role in host defense against mycobacteria
(Fig. 2.2). Although numerous gene polymorphisms have been identified which
influence host susceptibility to TB, it is apparent that in the vast majority of cases
susceptibility is polygenetic (Fitness et al. 2004). The complex interplay of multiple
genetic variants has yet to be fully elucidated. On-going genome wide association
studies (GWAS) studies should better illuminate genetic determinants of TB sus-
ceptibility and disease severity (O’Garra et al. 2013). In children immune maturation
is a major determinant of risk with infants (<2 years of age) being at highest risk of
disease development and potential dissemination (Perez-Velez and Marais 2012).
2.2 The Innate Immune Response
The key players in the innate defence against M. tuberculosis are the alveolar
macrophages and dendritic cells. Macrophages, dendritic cells and other immune
cells recognize mycobacterial structures, pathogen associated molecular patterns
(PAMPs) with membrane associated pattern recognition receptors (PRRs), of which
the most studied are the Toll-like receptors (TLR2, TLR4, TLR9). PAMPs such as
lipoarabinomannan, phosphatidylinositol and heat shock proteins (Hsp65 and
Hsp70), and mycobacterial nucleic acids, such as the CpG motif, are recognized by
TLRs. On interaction with the TLRs, signalling pathways are activated which lead
to the production of predominantly proinflammatory cytokines, such as TNF,
IL-1B, IL-12 and nitric oxide (Kleinnijenhuis et al. 2009; van Crevel et al. 2002).
Fig. 2.1 Transmission of TB
bacilli. Source CDC
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PRR-mediated phagocytosis of the pathogen by macrophages is an essential
feature of the innate immune response. Ingested bacteria are then destroyed through
phagosome-lysosome fusion and acidification (by H2O2 and other reactive oxygen
intermediates) however M. tuberculosis may subvert this process and evade
Fig. 2.2 Host genotype influences response to treatment with adjunctive steroids in Vietnamese
patients with TB meningitis. A Humans may have polymorphisms in the LTA4H gene locus,
which influence the severity of the inflammatory response. A process which is thought to be
analogous to the susceptibility of zebrafish to Mycobacterium marinum infection. B Patients with
the TT (high inflammatory) genotype, respond well to adjunctive treatment with dexamethasone.
From Tobin et al., Cell, 2012, reprinted with permission
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destruction (Sullivan et al. 2012). Essentially the innate immune response mediated
through macrophages can have three major results; (1) cell necrosis, (2) apoptosis
(3) survival of the infected macrophages. If the cell undergoes necrosis, myco-
bacteria are released and may infect new macrophages or disseminate whereas an
apoptotic cell membrane is not compromised and the bacteria are destroyed with the
macrophage. Survival of infected macrophages enables the mycobacteria to persist
and even proliferate before the adaptive immune response is activated by specific
T-cells that have been selected in the regional lymph nodes; generally 2–3 weeks
after primary infection (Saenz et al. 2013).
2.3 The Adaptive Immune Reponse
Dendritic cells are an important mediator between the innate and adaptive immune
response which in addition to phagocytosis, present live mycobacteria to naïve
T cells after migrating to regional lymph nodes. After antigen presentation in lymph
nodes, CD4+ T cells are activated, and migrate to the lungs to impede mycobac-
terial progressive growth. The crucial role of T-cells in immunity to mycobacteria is
evidenced by the dramatically increased susceptibility of individuals with HIV
infection. Susceptibility to TB increases as the CD4 cell count decreases. IFN-γ,
produced by activated T-cells, has a crucial role in protection against TB.
IFN-knock-out mice, and humans with impaired IFN-γ genes are highly susceptible
to severe TB disease (van Crevel et al. 2002). IFN-γ is essential in macrophage
activation and intracellular mycobacterial killing (Flynn et al. 1993). TNF-α is
another key cytokine produced by macrophages, dendritic cells and T cells and
plays a central role in granuloma formation, macrophage induction and has
immunoregulatory properties. Patients using TNF suppressing agent are at
increased risk of infection and reactivation. A Cochrane review of TNF-α inhibitors
given for any indication found a summary risk estimate odds ratio [OR] of 4.68,
[95 %CI: 1.18–18.60] for reactivation of TB compared to control groups (Singh
et al. 2011). However, TNF may also contribute to deleterious inflammatory
responses in patients with progressive disease.
2.4 The Complex Role of TNF and Its Genetic Control
Although it is observed that TNF suppression can cause more rapid progression to
TB disease, many aspects of the diverse functions of this proinflammatory factor
have yet to be elucidated (Souto et al. 2014; Murdaca et al. 2015). Currently it is
proposed that the effect of TNF on containment of mycobacterial infection is
achieved by mediating the maintenance of granuloma integrity by regulating
cell-adhesion proteins, chemokine attraction, and preventing T-cell dependent
granuloma disintegration and inflammatory destruction by regulating IFN
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producing CD4+ and CD8+ T cells. A second mechanism is by promoting apop-
tosis of mycobacteria containing macrophages, rather than non-apoptotic death,
thus preventing intercellular spread of bacteria (Miller and Ernst 2008).
It has been shown that in a Vietnamese population with TB meningitis that a
polymorphism in the LTA4H gene which leads to either excessive or deficient
TNF-α production can determine the response to adjunctive dexamethasone ther-
apy. This polymorphism was initially identified in a zebrafish model of myco-
bacterial infection (Cronan and Tobin 2014). TB meningitis patients with an
excessive TNF-α genotype appeared to benefit from adjunctive corticosteroids, with
decreased mortality. While for those with a low TNF-genotype, steroids may
actually be harmful, with increased mortality observed in this group when receiving
steroids. It is possible that similar naturally occurring variants in the LTA4H
genotype in all individuals exposed to TB may influence susceptibility and disease
progression. It is now becoming apparent that rather than a simplistic model of high
pro-inflammatory response being protective, the most protective response is bal-
anced between pro-and anti-inflammatory mediators, or ‘just right’, which has led
to the term ‘Goldilocks’ gene (Tobin et al. 2013).
2.5 The Tuberculoma
The hallmark of mycobacterial infection is the tuberculoma or granuloma. Our
current knowledge on granuloma development in the human in the different stages
of disease stems from meticulous post-mortem studies performed more than a
century ago. Granulomas are described by gross pathological appearance: solid or
non-necrotic, caseous or necrotic, or end-stage cavitary. Depending on the degree of
liquefaction, the caseum (from Latin, cheese-like), can be referred to as liquid/soft
or solid/hard. It is thought that in solid necrosis, the mycobacteria are more effi-
ciently contained, and generally less viable mycobacterium are found in hard ca-
seum. If sufficiently large, the granulomas may drain their (liquid) content into the
bronchial tree, releasing viable bacilli into the airways, to be aspirated into other
parts of the lung or coughed up and transmitted. If associated with parenchymal
destruction it heralds the onset of lung cavities, where extra-cellular bacilli multiply
exponentially. It has long been assumed that the granuloma formation serves the
host in containing the bacilli and preventing bacterial spread but it may also be
exploited by the bacilli to proliferate (Ramakrishnan 2012). Indeed many people
have evidence of healed granulomas, without having experienced active tubercu-
lous disease. However, it is evident that control of infection within granulomas are
not necessarily homogeneous within the same individual and ineffective in a sub-
stantial proportion of the global population.
On microscopic level the tuberculous granuloma is an organized aggregation of
immune cells and debris. It contains macrophages that have undergone morpho-
logical change into epithelioid cells which form into zipper-like arrays around the
necrotic centre. They retain the ability to phagocytise mycobacteria. Macrophages
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can also fuse to form multinucleated giant cells and foam cells, which have high
lipid contents, but only few bacteria and their protective role is uncertain. Other cell
types surrounding the granuloma are dendritic cells, neutrophils, B cells, T cells,
natural killer (NK) cells, fibroblasts. Epithelial cells often are found in the outer
layer of the granuloma. Mycobacteria are concentrated in the periphery of the
central necrotic area.
2.6 Vitamin D and the Immune Response
In the pre-antibiotic era TB patients were often treated with cod-liver oil and
sunshine, both sources of 25-hydroxyvitamin-D, which has immunomodulatory
properties. Currently the interest in the role of vitamin D-status in susceptibility to
TB and the use of vitamin D adjunctive to antimycobacterial treatment has been
re-ignited (Nunn et al. 2013). Particularly in the context of multi drug resistance,
adjunctive treatment with vitamin D may be of importance in TB patients as,
second-line treatment regimens are less bactericidal and should be paired with an
optimal immune response in order to effectively eliminate infection.
2.6.1 Vitamin D Metabolism
Vitamin D is historically associated with bone disease for its role in maintenance of
calcium homeostasis by promoting calcium absorption in the intestines and bone
resorption, processes which are regulated by parathyroid hormone. However, the
anti-inflammatory properties of vitamin D are increasingly being investigated by
researchers globally in the context of other conditions, such as diabetes, infectious
and autoimmune diseases and cardiovascular disease (Theodoratou et al. 2014).
Dietary sources of vitamin D are limited, however fish liver oils and fatty fish
naturally contain vitamin D. It is difficult however to get the acquired intake of
vitamin D solely from natural dietary sources. Sunlight is a another source of
Vitamin D, as after exposure to ultraviolet B, 7-dehydrocholesterol in the plasma
membrane of human keratinocytes is converted to previtamin D3, from which
vitamin D3 (cholecalciferol) is formed. Vitamin D is fat soluble and is carried in the
circulation by hepatically produced vitamin D-binding protein. In the liver, vitamin
D is hydroxylated to form 25-hydroxyvitamin (25(OH)D) (also known as calcidiol,
the serum measure of vitamin D), which is converted to the steroid hormone
1,25-dihydroxyvitamin D (calcitriol, the biologically active metabolite) in the
kidneys. The actions of the hormone are mediated either through ligation with a
nuclear vitamin D-receptor (VDR) to regulate gene transcription, resulting in
genomic responses, or via membrane rapid-response receptors (Ralph et al. 2013;
Coussens et al. 2014).
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2.6.2 Antimicrobial Effects of Vitamin D
Several mechanisms are proposed by which vitamin D may exert antimycobacterial
properties and enhances the immune response. In particular the transcription of
cathelecidin is completely dependant on sufficient levels of 1,25-hydroxyvitamin D
(Aranow 2011). Cathelecidin destroys microbial membranes in the phagolysosome
in macrophages.
2.6.3 Vitamin D Deficiency and Susceptibility
to Tuberculosis
Vitamin D deficiency has been implicated to play a role in increased susceptibility
to active TB disease in numerous studies.
25-hydroxyvitamin-D receptors are present on all immune cells, including
macrophages, and are upregulated after stimulation of Toll-like receptors, which
play a central role in mycobacterial recognition. Polymorphisms in the VDR
receptor potentially modulate the activity of the receptor and thus the action of
Vitamin D. A meta-analysis of the most widely studied polymorphisms in the VDR
(FokI, TaqI, ApaIand BsmI) and susceptibility to TB, showed that among Asians,
the FokIff genotype had a positive association (OR 2.0, 95 %CI 1.3–3.2) with TB,
whereas, a significant inverse association was observed for the BsmI bb genotype
(OR 0.5, 95 %CI 0.4–0.8). Marginal significant associations were found for TaqI
and ApaI polymorphisms (Gao et al. 2010).
A meta analysis of 7 studies on vitamin D status and susceptibility to TB,
including 531 individuals found that patients with tuberculosis have lower average
pre-treatment serum levels of vitamin D than healthy controls matched on sex, age,
ethnicity, diet and geographical location. The pooled effect size in random effects
meta-analysis was 0.68 (95 %CI 0.43–0.93) (Nnoaham and Clarke 2008).
A systematic Cochrane review in 2011 found no consistent evidence of bene-
ficial impact on TB treatment outcomes for micronutrient supplementation,
including vitamin D (Sinclair et al. 2011). Supplementation of patients on treatment
for pulmonary TB has been associated with accelerated resolution of inflammatory
responses (Coussens et al. 2012). Supplementation led to accelerated clinical and
radiological recovery as well as an enhanced immune response in those with
deficient serum vitamin D at diagnosis in a recent trial (Salahuddin et al. 2013)
(Fig. 2.3).
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Fig. 2.3 Schematic representation of basic immunological antimycobacterial mechanisms in the
lung and lymphnode. Macrophages and dendritic cells initially encounter Mycobacterium
tuberculosis (M.TB) in the lung. A After ingestion, macrophages can undergo apoptosis or
necrosis. After necrosis, bacterial spread may ensue. Surviving macrophages assist in early
granuloma formation, either leading to elimination or clinical latency. B The mycobacteria can
evade the immune response by inhibiting phagolysosome formation and apoptosis, as well as
blocking the response of macrophages to IFNγ. C Resident dendritic cells of the lung can travel to
regional lymphnodes, presenting live mycobacteria and mycobacterial antigen, activating naïve
T-cells, B-cells and regulatory T-cells. D In the lung, activated T-cells and B-cells (attracted to the
lung by chemokines) control bacterial growth by production of cytokines and antibodies.
Regulatory T-cells control the inflammation through the production of IL-10 and TGF-β. Adapted




Abstract In this chapter we will review the clinical manifestations of tuberculosis
disease.
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3.1 Primary Tuberculosis
Primary (initial) infection is usually indicated by tuberculin skin test (TST) or
interferon-gamma release assay (IGRA) conversion, which reflects a delayed type
hypersensitivity reaction to protein products of M. tuberculosis. TST conversion
usually occurs 3–6 weeks after exposure/infection; guidelines for its correct inter-
pretation can be found at: http://www.cdc.gov/tb/publications/factsheets/testing/
skintesting.htm. Primary infection remains undiagnosed in the majority of cases, as
symptoms are mild, non-specific and usually self-resolving. A primary (Ghon)
complex is formed, consisting of a granuloma, typically in the middle or lower
zones of the lung (primary or Ghon focus) in combination with transient hilar
and/or paratracheal lymphadenopathy and some overlying pleural reaction. The
primary complex usually resolves within weeks or months, leaving signs of fibrosis
and calcification detectable on chest X-ray. In general the risk of disease progres-
sion following primary infection is low, but young children and immunocompro-
mised patients are at increased risk.
The natural history of a re-infection event is not well described, since we have no
good measure of its occurrence. We know it is likely to be common in TB endemic
areas, since molecular epidemiological evidence suggests that many disease epi-
sodes (the vast majority in some settings) result from currently circulating strains,
representing recent infection/re-infection. A re-infection event probably triggers
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very similar responses to those observed with primary (first-time) infection and the
risk of subsequent disease progression seems to be substantially reduced. However,
re-infection is likely to occur multiple times during the lifetime of an individual
living in a TB endemic area, which explains its large contribution to the disease
burden observed.
Reactivation disease or post-primary TB are often used interchangeably for TB
occurrence after a period of clinical latency. However, since reactivation disease is
clinically indistinguishable from progressive primary disease or re-infection disease
(DNA fingerprinting is required to distinguish reactivation from re-infection) the
terminology is not descriptive or clinically useful. True reactivation disease is often
preceded by an immunological impetus. Patients with immunocompromise due to
severe malnutrition, HIV-infection, chronic hemodialysis, immunosuppressive
therapy, diabetes or silicosis etc. are at increased risk.
3.2 Pulmonary Tuberculosis
TB symptoms are usually gradual in onset and duration varying from weeks to
months, although more acute onset can occur in young children or immunocom-
promised individuals. The typical triad of fever, nightsweats and weightloss are
present in roughly 75, 45 and 55 % of patients respectively, while a persistent
non-remitting cough is the most frequently reported symptom (95 %) (Davies et al.
2014). Approximately 20 % of active TB cases in the US are exclusively extra-
pulmonary (EPTB), with an additional 7 % of cases having concurrent pulmonary
and EPTB (Peto et al. 2009).
3.2.1 Parenchymal Disease
Patients with cavitary lung disease typically present with (chronic) cough, mostly
accompanied by fever and/or nightsweats and weightloss. Cough may be
non-productive or the patient may have sputum, that can be mucoid, mucopurulent,
blood-stained or have massive haemoptysis. Other symptoms may be chest pain, in
patients with subpleural involvement, or dyspnoea, however rare. Upon ausculta-
tion, the findings in the chest may be disproportionally normal to the findings on
chest X-ray. The results of the chest X-ray may be critical for treatment initiation
for those patients who are sputum smear negative. In particular in low resource
countries, chest X-ray interpretation is often done by non-expert medical staff, and
missed diagnosis is common. Typical findings include normal chest X-ray, focal
upper lobe opacities, diffuse opacities, consolidation, reticulonodular opacities,
cavities (Fig. 3.1a), nodules, miliary pattern (Fig. 3.1b), intrathoracic lymphade-
nopathy, pleural effusion. In HIV-infected patients, smear yield is lower and
radiological abnormalities may be less typical, frustrating diagnosis. Severely
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immune-suppressed patients and young children are less likely to present with
cavitation on chest X-ray, and more frequently have miliary (disseminated) disease.
3.2.2 Endobronchial Tuberculosis
Endobronchial TB is a specific form of pulmonary TB affecting the trachea and major
bronchi. It is often misdiagnosed as bronchial asthma or bronchial malignancy. If
unrecognized, the endobronchial lesions progress and cause stenosis. Symptoms are
as those of pulmonary TB, however examination may include wheezing and dysp-
noea may be more prominent. There may be a female predominance, with a male:
(a) (b)
(d)(c)
Fig. 3.1 a Chest X-ray showing cavitary lung lesions (white arrow) and upper lobe opacities
(smaller red arrows) in 46 year old male. b Chest X-ray with the classic ‘scattered millet seed’
appearance of milliaryTB 49 year old female. c Magnetic resonance image (MRI) of a 35 year old
female with spinal TB, showing destruction of thoracic vertebral bodies (T8 and T9) and
compression of the spinal cord. d MRI scan showing tuberculoma (large white arrow), basal
meningeal enhancement (small red arrows) and hydrocephalus (blue arrow) in a 2 year old child
with tuberculous meningitis
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female ratio of 1:2 (Qingliang and Jianxin 2010; Xue et al. 2011). Bronchoscopy and
biopsy is the most useful diagnostic tool and to establish a prognosis depending on
which histological subtype is found. Sputum smear and culture should be performed,
but varying test sensitivities are reported. Early therapy is needed in order to prevent
strictures, treatment with standard first-line short-course regimen (see Treatment
section), but treatment prolongation may be considered on a case by case basis, for
those patients with intractable disease (Xue et al. 2011).
3.2.3 Intra-Thoracic Lymphnode Disease
Following first-time infection the regional lymph nodes form part of the primary
(Ghon) complex. Progressive disease may occur within these affected regional
lymph nodes and is typically seen in young children. Symptoms are similar to those
described for other forms of pulmonary TB, although the cough is rarely productive
or the sputum blood-stained. Young children are unable to expectorate and the
organism load is greatly reduced compared to adults with lung cavities, which
complicates diagnosis (Perez-Velez and Marais 2012). Enlarged peri-hilar and/or
paratracheal lymph nodes may obstruct large airways with resultant collapse or
hyperinflation of distal lung segments, form cold abscesses with persistent high
fever, or erode into surrounding anatomical structures such as the pericardium
leading to TB pericarditis. Peri-hilar and/or paratracheal lymph node enlargement
with/without airway compression is the cardinal sign of intra-thoracic lymph node
disease. Lymph nodes may also erupt into the airways with aspiration of infectious
caseum leading to lobar consolidation and an expansile caseating pneumonia if the
airway is completely obstructed.
3.3 Extra-Pulmonary Tuberculosis
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3.3.1 Pleural Tuberculosis
Between 3 and 25 % of TB patients will have tuberculouspleuritis or pleural TB. As
with all forms of extrapulmonary TB, incidence is higher in HIV-infected patients.
In some high burden countries, TB is the leading cause of pleural effusions. Typical
presentation is acute with fever, cough and localized pleuritic chest pain. It may
follow recent primary infection or result from reactivation. If part of primary
infection, the effusion may be self-limiting. However, if it occurs in pregnancy it
signals a potential risk to foetus, since recent primary infection is frequently
associated with the occult dissemination. TB pleural effusions are usually unilateral
and of variable size. Approximately 20 % of patients have concurrent parenchymal
involvement on chest X-ray, however CT-scans have higher sensitivity and may
detect parenchymal lesions in up to 80 % of patients (Light 2010). HIV infected
patients may present with atypical symptoms, often with less pain and longer
duration of illness and more generalized signs.
Pleural fluid is mostly lymphocytic with high protein content. Bacillary load is
generally low and smear is typically negative, although this may be higher in HIV
positive patients, in whom diagnostic yield from smear may be as high as 50 %.
Elevated levels of adenosine deaminase (ADA) may be indicative; sensitivity and
specificity estimates from a meta-analysis of published studies were 92 and 90 %
respectively, with a cut-off value of 40U/l (Liang et al. 2008). However ADA levels
can be increased in other diseases, such as empyema, lymphomas, brucellosis, and
Q fever, and the test cannot differentiate between these diseases. A negative result
suggests that TB is unlikely, but should always be interpreted in the clinical context.
Pleural biopsy may show granuloma in the parietal pleura and are highly suggestive
of TB, even in the absence of caseation or AFB. Stain and culture of the pleural
biopsy is reported to have a higher yield than pleural fluid (positive results in
approximately 25 and 56 % of biopsies respectively) (Light 2010).
3.3.2 Miliary Tuberculosis
Miliary TB can occur during primary infection and in post-primary disease. It
indicates dissemination of disease and arises from the haematogenous spread of
bacilli, which may occur shortly after primary infection or from any active disease
site. Miliary granulomas are 1–3 mm in diameter (the size of a millet seed (Latin:
milia)), are widespread and may be found in any visceral organ (Davies et al. 2014).
In immunocompetent patients, miliary TB accounts for approximately 3 % of TB
cases and is more commonly found in immunocompromised patients (>10 % of
HIV-infected patients) and in young children (Sharma et al. 2005).
Clinical symptoms are mostly constitutional, including malaise, fever, weight-
loss, sweats, anorexia. Pulmonary signs may be similar but often less pronounced
than in uncomplicated pulmonary TB. If the brain is involved, neurological
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symptoms may include headache, reduced consciousness and cranial nerve palsies.
Involvement of other organs usually does not elicit localized symptoms. In
immunocompromised patients physical signs may be less apparent and include
dyspnoea, wasting, lymphnode enlargement, hepatosplenomegaly, cutaneous
lesions. These patients are more at risk of meningeal involvement. Cutaneous
involvement is rare (tuberculosis miliaria cutis), but if present may provide a
valuable clue to the diagnosis. Rare complications including adult respiratory dis-
tress syndrome (ARDS), pneumothorax, cardiac and multi-organ dysfunction have
been described. Due to the non-specific symptomatology, miliary TB is often only
be discovered at post-mortem. A chest radiograph is pivotal in diagnosis, but is
notoriously treacherous (Fig. 3.1b). A high index of suspicion is needed to be able
to perceive the fine nodular lesions in more obscure cases. In uncertain cases, (high
resolution) CT-scan is more sensitive in detecting the miliary lung nodularity
(Sharma et al. 2005). Miliary TB may be accompanied by consolidation (30 %),
parenchymal lung cavities (3–12 %), or mediastinal and/or hilar lymphadenopathy
(15 %) on chest X-ray (Sharma et al. 2005). A missed diagnosis is grave, as
untreated miliary TB often leads to TB meningitis and can be rapidly fatal.
Rapid diagnostic confirmation is not easily achieved, since cough is often
non-productive, the sensitivity of conventional sputum smear is low. Smear may be
performed on other bodily fluids such as gastric fluid, urine, cerebrospinal fluid,
bronchial lavage and pleural fluid. Sputum culture may be positive in 30–60 % of
patients. Tissue biopsy or fine needle aspiration may be indicated and should be
sent for smear and biopsies examined for granulomatous disease. In tissue biopsies
(liver, bonemarrow, transbronchial, pleura or lymphnode) confirmation rate is high
and a diagnosis may be found in up to 83 % of cases.
3.3.3 Extra-Thoracic Lymphnode Disease
Cervical lymphadenitis (scrofula) is the most common form of extra-pulmonary
TB. In the middle-ages it was known as ‘the King’s evil’ because it was believed
the touch of royalty could cure the disease. Before the pasteurization of milk, the
more likely causative agent wasMycobacterium bovis, which is non-distinguishable
from M. tuberculosis on ZN stain. Some non-tuberculous mycobacteria (NTM) are
known to cause lymphadenitis: Mycobacterium scrofulaceum, Mycobacterium
avium-intracellular complex, Mycobacterium malmoense, Mycobacterium fortui-
tum, Mycobacterium chelonei and Mycobacterium kansassi, of which
Mycobacterium avium-intracellular complex is the most common causative agent
(Handa et al. 2012). The route of entry is thought to be through ingestion, via the
oropharyngeal mucosa or tonsils, or through skin abrasions.
In the US, lymphadenitis accounts for 40 % of extra-pulmonary TB cases. The
most common site is the cervical region, followed by mediastinal, axillary, mes-
enteric, hepatic portal, peripancreatic, and inguinal lymphnodes (Rieder et al.
1990). Lymph node involvement may follow first-time infection as part of the
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primary (Ghon) focus, with subsequent haematogenous or lymphatic spread, with
reactivation of a dormant focus or with direct extension of a contiguous focus.
The patient usually presents with a palpable (lymph node) mass greater than
2 × 2 cm and mostly in the cervical area (60 %), either in the jugular, posterior
triangle or supraclavicular region, with or without fistula or sinus formation (Handa
et al. 2012). Other complications are overlying violaceous skin inflammation and
cold abscess formation. Tenderness or pain is not typically described, unless there is
secondary bacterial infection. Generalised constitutional symptoms and pulmonary
symptoms or signs may be absent, but are more often reported in HIV-infected
patients. The differential diagnosis includes bacterial adenitis, fungal infection, viral
infection, toxoplasmosis, cat-scratch disease, neoplasms (lymphoma, metastatic
carcinoma, Hodgkin’s disease, sarcoma), sarcoidosis, drug reactions and
non-specific hyperplasia.
The history is important and chest X-ray should be obtained but may be normal
in the majority. TST may be helpful in non-endemic countries, reported positive in
over 85 % of patients, however it may be negative in patients with HIV infection
and non-tuberculous lymphadenitis (Razack et al. 2014).
Diagnosis is classically confirmed by excisional biopsy and histological and
microbiological examination. Incisional biopsy has been associated with increased
risk of sinus tract formation and is not recommended. Caseating granulomatous
inflammation with Langhans and giant cells is highly suggestive of TB. Positive
culture from biopsies are reported in between 60 and 80 %, with even higher rates
reported fine needle aspiration biopsy (FNAB), which has replaced more invasive
biopsies as the diagnostic procedure of choice (Handa et al. 2012). The diagnosis of
lymph node TB can be achieved with a combination of FNAB cytology (detection
of epithelioid cells), AFB smear, PCR and culture in over 80 % of cases (Razack
et al. 2014).
3.3.4 Central Nervous System Tuberculosis
The most common clinical manifestation of central nervous system (CNS) TB is
tuberculous meningitis (TBM). Other entities are CNS tuberculoma, which may be
present without symptoms or rarely with seizures, tuberculous encephalopathy
(rare, only described in children) and tuberculous radiculomyelitis. Pathogenesis is
thought to be through a two-step process, in which heamotogenous spread leads to a
tuberculous focus (Rich focus) in the brain, which then invades and release bacilli
in the subarachnoid space (Donald et al. 2005). In HIV-infected patients and young
children it is more often associated with miliary disease, which may indicate more
direct haematogenous spread in these patients. TBM is the most lethal form of TB.
Almost a third of HIV uninfected patients, and more than half of patients that are
co-infected with HIV die from TBM, despite treatment. Half of the survivors suffer
from permanent neurological impairment (Thwaites et al. 2004).
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Early recognition and appropriate treatment are key to improved outcome. Early
symptoms are non-specific, including the suggestive triad of fever, nightsweats and
weightloss and headache of increasing intensity. A duration of symptoms (headache
and fever) of more than 5 days should prompt clinicians to include TBM in the
differential diagnosis. In the more advanced stages patients become more confused,
present with reduced consciousness, hemiplegia, paraplegia and urinary retention
(seen with spinal involvement) and cerebral nerve palsies, most frequently involved
is nerve VI (up to 40 % of cases), but also III and VII. Seizures are not frequently a
presenting symptom in adults (seen in less than 5 % of cases), however often
reported in children (50 % of TBM cases). Movement disorders may be seen and
are associated with typical basal ganglia involvement. Upon examination, nuchal
rigidity is typically less pronounced than in acute bacterial meningitis. Sixth nerve
palsy is pathognomonic (Thwaites and Tran 2005).
Diagnosis is often based on a clinical algorithm rather than mycobacterial iso-
lation. Typical features on cerebral imaging on presentation are basal meningeal
enhancement, hydrocephalus, and tuberculoma solitary or multiple (MRI shown in
Fig. 3.1d). Cerebral infarction may occur during treatment, mostly in the basal
ganglia, or paradoxical tuberculoma may form. The cerebrospinal fluid (CSF) is
paucibacillary, thus diagnosis confirmed by AFB smear of the CSF is relatively rare
(less than 20 % in most laboratories). CSF cellularity is typically lymphocytic
(although neutrophils may predominate in the early stages), has raised protein
content and moderately raised lactate (typically between 3 and 8 mmol/l), in con-
trast with bacterial meningitis in which lactate is generally higher. Raised ADA
may aid diagnosis, however is not specific, particularly for the differentiation of
bacterial meningitis (Tuon et al. 2010). If TBM is suspected, large volumes (>6 ml)
of CSF should be drawn and concentrated by centrifugation in order to facilitate
microbiological confirmation. Meticulous examination of the smear for up to
30 min can significantly increase detection to over 60 % of those clinically diag-
nosed (Thwaites et al. 2004).
In contrast to pulmonary TB where sputum smear is less often positive in
HIV-infected individuals, CSF is more often positive in HIV-infected individuals
with TBM. Liquid culture still provides the ‘gold standard’ (positive cultures found
in approximately 65 % of clinical TBM cases), however results take 2–4 weeks and
should not be awaited for treatment initiation. Xpert MTB/RIF is more sensitive than
conventional smear and WHO currently recommends this PCR based test for the
diagnosis of TBM (Nhu et al. 2013; World Health Organization 2013). The current
treatment guidelines are extrapolated from pulmonary regimens, with durations
varying from 9 to 12 months of at least 4 first-line agents and including adjunctive
corticosteroids (Prasad and Singh 2008; Chiang et al. 2014). However a recent study
suggests that the addition of fluoroquinolones and higher doses of rifampicin may
improve treatment outcome, since CSF penetration of most of the first-line TB drugs
(particularly rifampicin, streptomycin and ethambutol) is poor (Ruslami et al. 2012).
Surgical intervention may be indicated in cases with severe non-communicating
hydrocephalus and large tuberculousabcesses.
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3.3.5 Tuberculous Pericarditis
Cardiac TB most frequently involves the pericardium. TB endocarditis or
involvement of the myocardium is extremely rare. Clinical progression is charac-
terized by insidious onset, classically with a presentation with fever of unknown
origin. Upon examination a pericardial friction rub may be auscultated. ECG
changes consist of diffuse ST elevations, without reciprocal changes, T wave
inversion, PR segment deviations. Typical changes as found in acute pericarditis
(The PR-segment deviation and ST-segment elevation) are only found in roughly
10 % of cases (Mayosi et al. 2005). Usually the rise in erythrocyte sedimentation
rate (ESR) and C-reactive protein (CRP) are less marked compared to the same
parameters measured in viral or bacterial pericarditis. A chest X-ray may reveal left
pleural effusion, however this is a non-specific finding. Echocardiogram is central
in diagnosis, revealing effusion and if present, tamponade. Confirmation of diag-
nosis is by demonstration of AFB in the pericardial aspirate by smear. In pericardial
TB the sensitivity of smear is 15–20 % and of mycobacterial culture 30–75 % (Gooi
and Smith 1978). The presence of cardiac tamponade is the most predictive sign of
later development of constrictive pericarditis.
The optimal treatment duration remains uncertain, but suggested treatment
regimens range from 6 to 12 months. The addition of corticosteroids as an adjuvant
to prevent further accumulation of fluid and the development of constrictive peri-
carditis is recommended (Fowler 1991; Mayosi et al. 2005). Open surgical drainage
may be indicated to prevent tamponade, however little data exists on the benefit of
closed percutaneous drainage (Reuter et al. 2007).
3.3.6 Spinal Tuberculosis
Spinal TB can cause deformities, typically kyphosis, in extreme forming a gibbus,
which can result in paraplegia. Depictions of sufferers are found originating from
Ancient Egypt 5000 years ago. Since the late 18th century it became known as
Pott’s disease. After haematogenous spread, tuberculous spondylitis develops,
initially affecting a single vertebra, but with progressing of infection, softening may
result in wedging or collapse of the vertebral body and subligamentous spread may
involve adjacent vertebrae (Jung et al. 2004). Cold abscesses formation or severe
spinal angulation may cause compression of the spinal cord with neurological
sequelae. In rare instances bacilli may be released into the subarachnoid space,
leading to meningitis, or an abscess may drain externally with sinus formation
(Cheung and Luk 2013).
MRI is the imaging modality of choice (Fig. 3.1c) (Jung et al. 2004). Evidence
of pulmonary TB or other organ involvement, should heighten suspicion and
provides an opportunity for the collection of samples for microbiological exami-
nation. Confirmation of diagnosis relies on the detection of AFB on CT-guided
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tissue biopsies or abscess aspirates. Treatment regimens are as for pulmonary TB,
however some advocate longer duration of treatment. Based on the results of a
series of randomized clinical trials conducted by the MRC Working party on TB of
the spine, spanning a period of 15 year follow up, it is currently accepted that early
and mild disease, without significant neurological deficits, may be treated conser-
vatively with anti-tuberculous chemotherapy without operative intervention.
Patients treated with debridement alone or combined with spinal fixation (with
anterior strut graft) had the tendency to earlier resolution of abscesses, earlier bony
fusion and less kyphotic deformity (Mak and Cheung 2013). It is important to
identify the poor prognostic factors that are associated with severe kyphosis
development, such as the degree of vertebral body loss before treatment, and the
separation of facet joints, to identify patients that would benefit for operative
intervention by reducing kyphotic deformity.
3.3.7 Other Forms of Extra-Pulmonary Tuberculosis
Tuberculous arthritis, almost always affects only a single joint, usually the hip and
knee. It can be diagnosed by examination of synovial fluid or synovial tissue
biopsies. Gastrointestinal TB may mimic Crohn’s disease, both clinically and
radiographically. Preferred sites are the ileocecum, ileum and jejunum and is
usually associated with peritonitis. Barium contrast studies can reveal ulceration,
strictures, bowel wall thickening, skip lesions and fistulae. In endemic countries,
diagnosis is usually made on clinical suspicion. Biopsies may be useful in estab-
lishing the diagnosis (Nagi et al. 2002, 2003).
Urogenital TB is notoriously asymptomatic. TB of the urinary tract, occasionally
causes flank pain or present with a renal or pelvic mass. Persistent “sterile” pyuria
on urine analysis, especially early morning samples, require further investigation
with urine AFB smear, PCR and culture. Further investigations include intravenous
urography (Merchant et al. 2013a, b).
Laryngeal TB is one of the most infectious forms of TB. Sputum smear is reported
positive in up to 70 % of cases. It can result from primary infection with infected
droplet nuclei or secondary to pulmonary disease. Hoarseness and dysphagia can be
among the presenting signs. Laryngeal TB can be primary, when bacilli directly
invade the larynx or secondary from bronchial spread of advanced pulmonary TB
(Benwill and Sarria 2014). It presents with hoarseness and dysphagia, or chronic
cough if associated with pulmonary TB (Michael and Michael 2011). It should be
differentiated from laryngeal malignancy. TB can potentially affect any organ in the
human body, further discussion of all rare forms fall beyond the scope of this chapter.
Open Access This chapter is distributed under the terms of the Creative Commons Attribution
Noncommercial License, which permits any noncommercial use, distribution, and reproduction in
any medium, provided the original author(s) and source are credited.
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Chapter 4
Diagnosis
Abstract At the turn of the century, it was widely recognized that an accurate
point-of care test for TB was required to make significant reductions in the pan-
demic. At this time, many novel tests had been developed by research groups or
small biotech companies, but had never been standardized or evaluated for scale-up
and application in low-resource, high-burden settings where the need is greatest.
This motivated a major drive to systematically evaluate existing tests such as
commercial liquid culture and nucleic acid amplification tests (NAAT), and to
develop new approaches, principally led by the Foundation for Innovative New
Diagnostics (FIND www.finddiagnostics.org) in collaboration with industry, gov-
ernment and clinical partners. The evidence generated by this renewed focus on
novel TB diagnostic tests, processes and algorithms has led to a substantial number
of policy revisions and new WHO recommendations (Table 4.1, see also www.
tbevidence.org).
Keywords Smear microscopy  Ziehl neelsen stain  Mycobacterial culture 
Nucleic acid amplification tests (NAAT)  Xpert MTB/RIF  GeneXpert  Line
probe assay  Drug-resistant tuberculosis  Interferon gamma release assays (IGRA)
4.1 Smear Microscopy
The confirmation of TB disease still rests upon identification or isolation of
M. tuberculosis bacilli from a clinical sample. This can be achieved by smear
microscopy for acid-fast bacilli (AFB), mycobacterial culture or nucleic acid
amplification (NAAT) tests. The appropriate sample will depend upon the sus-
pected site of disease. The quality of the sample may greatly affect the chances of a
positive result therefore care should be taken to instruct the patient in producing a
sputum sample. Children are often unable to produce sputum and in young children
gastric aspirate is usually necessary.
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Diagnosis for the majority of patients worldwide suspected of TB is still made
by sputum smear microscopy for acid-fast bacilli. The test, which was developed
100 years ago by Franz Ziehl and Frederick Neelsen, is inexpensive, simple, rapid
and specific but is only positive in around half of patients with active TB. The
Ziehl-Neelsen smear exploits the acid-fast property of mycobacteria by staining
bacilli with carbol-fuschin, using gentle heat to facilitate penetration of the dye, and
then using a decolorising acid solution, which fails to penetrate the mycobacteria,
leaving them stained red while other bacilli are decolorised. The slide is usually
then counterstained with methylene blue to improve visualization of the myco-
bacteria (World Health Organisation 1998). The Kinyoun stain is an alternative
cold-stain method. The sensitivity of the test is substantially lower in children and
patients with HIV. In addition the test is not specific for M. tuberculosis, but detects
all acid-fast bacilli including NTMs. Sensitivity may be increased by concentration
of samples prior to microscopy, usually by centrifugation or filtration (Van Deun
et al. 2000) but direct (unconcentrated) ZN stain is the most widely applied
methodology due to resource limitations.
Traditional TB control focused on the identification and treatment of sputum
smear-positive TB patients, considered to be most infectious cases, in the mistaken
belief that systematic identification and treatment of smear-positive cases would be
sufficient to reach eventual TB elimination. Recent efforts to improve the sensitivity
of basic smear microscopy have developed improved fluorescent microscopes to
decrease the reading time and increase the sensitivity of smear microscopy without
significantly affecting specificity if training and quality control are maintained.
WHO now recommends the replacement of conventional microscopy with fluo-
rescent microscopy wherever possible, using rugged and energy efficient LED
fluorescent microscopes that can be battery operated. In a further policy change,
WHO recommended in 2010 that two sputum samples are sufficient, rather than the
standard three samples (spot-morning-spot) which had been recommended for
several decades (World Health Organisation 2010). This is due to the low diag-
nostic yield of a third sputum sample and the resource limitations of TB pro-
grammes. If clinical suspicion is high repeated testing may still be warranted.
A single positive smear is now also considered sufficient for a TB diagnosis
(Bonnet et al. 2007; Mase et al. 2007).
4.2 Mycobacterial Culture
Culture of M. tuberculosis is a more sensitive technique for diagnosis but due to the
slow growth of the organism (replication time of 24–30 h) sputum cultures take
4–6 weeks to become positive on solid media and 10–21 days in liquid media. Solid
culture is usually performed on Lowenstein Jensen (LJ), Ogawa or Middlebrook
7H10/11 agar media. Liquid culture of M. tuberculosis is more sensitive and rapid
than solid culture but can be prone to contamination in some laboratories. Early
commercial automated liquid culture systems for mycobacteria used radiometric
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assay but have now been replaced with fluorescence based quenching systems
which has improved safety. The most widely used system is the Bactec
Mycobacterial Growth Indicator Tube (MGIT) (Becton Dickinson, Sparks,
Massachusetts) system which can also be used for susceptibility testing to first line
drugs using a commercially available kit. A culture is necessary to confirm drug
susceptibility, particularly for second-line drugs in cases of multi-drug resistance
(MDR TB). M. tuberculosis culture and phenotypic DST requires significant
training, infrastructure, strict infection control and on-going quality assurance,
which is only available in regional reference laboratories in most countries.
4.3 Nucleic Acid Amplification Tests
Various commercial and in-house nucleic acid amplification tests (NAAT) have
been available since the 1990s. Detection of M. tuberculosis in clinical samples is
generally less sensitive than NAAT for other pathogens due to the relatively low
numbers of bacilli present and the difficulty of efficiently extracting DNA from the
tough mycobacteria. The development of Line Probe assays (LPA) allowed the
simultaneous detection of M. tuberculosis and determination of resistance to rif-
ampicin and later isoniazid. However these tests are only endorsed for use on smear
positive sputum and therefore do not aid greatly in the diagnosis of TB itself. The
MTBDR-Plus assay (HainLifesciences, Nehren, Germany) has recently been
adapted to enhance detection for use on smear negative sputum samples but
large-scale evaluation data is not yet available. The use of LPA for detection of drug
resistance is discussed in more detail in the section on diagnosis of drug resistance
below.
The most significant advance in the diagnosis of TB in the last decade has been
the advent of the GeneXpert MTB/RIF test (Cepheid, California, USA). This test
system was originally developed for testing for the presence of anthrax spores in the
United States bioterrorism-scares. A specific cartridge was later developed to detect
M. tuberculosis and simultaneously determine resistance to rifampicin. In 2010
results of a multi-country demonstration study sponsored by FIND demonstrated
that the Xpert MTB/RIF test detected TB and rifampicin resistance with high
sensitivity and specificity compared to liquid culture; confirmed by a Cochrane
review in 2013. The test was officially endorsed by WHO, followed by an
unprecedented rapid scale up of the new technology [http://who.int/tb/laboratory/
mtbrifrollout/en/]. A key factor in wide-scale implementation was a negotiated price
reduction facilitated by a large guaranteed buy-down from UNITAID, USAID,
PEPFAR and the Bill and Melinda Gates Foundation which reduced the price per
cartridge from more than 40 USD to less than 10 USD for public health facilities in
141 low and middle income countries. A major advantage of the Xpert MTB/RIF
test is the ability to detect smear negative TB in HIV-infected individuals (World
Health Organization 2013).
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In 2013 WHO issued updated policy guidance on the use of Xpert MTB/RIF
additionally endorsing its application for extrapulmonary and pediatric samples.
This policy update expanded the recommended application of Xpert MTB/RIF to
include pediatric and extrapulmonary samples, including gastric aspirate, lymph
aspirate, pleural fluid and cerebrospinal fluid. There was insufficient evidence to
estimate sensitivity with urine, pericardial fluid and ascitic fluid, although speci-
ficity is generally high with these sample types. Optimal sample processing for
blood and stool samples has not been determined and therefore the Xpert MTB/RIF
test is not recommended pending further research. Full recommendations can be
found at http://tbevidence.org/wp-content/uploads/2013/11/WHOstat.pdf.
By facilitating early detection of TB, prior to smear positivity, the application of
Xpert MTB/RIF should have a significant impact on transmission chains and push
back the epidemic. However, many of the patients diagnosed by Xpert MTB/RIF
would have been initiated on treatment due to chest X-ray findings or clinical
findings consistent with TB and the extent to which the use of Xpert MTB/RIF will
increase case finding is not yet clear. Theoretical modelling studies suggest that the
application of the test will improve targeting of treatment, with less patients who do
not have TB incorrectly started on treatment and a greater number of smear negative
‘true TB’ cases detected. South Africa has implemented the Xpert MTB/RIF test
nationwide and data on the cost-effectiveness and impact on the epidemic are
Fig. 4.1 Current development in TB diagnostics. Only the Xpert® MTB/RIF has received WHO
endorsement. From UNITAID, Diagnostic technology and market landscape, 3rd edition, 2014.
Reprinted with permission
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eagerly awaited. Although relatively simple to perform and rapid, the Xpert
MTB/RIF is not a true point-of-care test and many challenges have been encoun-
tered during scale-up. The need for a reliable electricity supply is a major barrier in
some settings, problems with module calibration and maintenance, the need for the
bulky cartridges to be stored below 30 °C, determining optimal testing algorithms
and logistics of kit supply have been some of the challenges encountered
(Abdurrahman et al. 2014) (Fig. 4.1).
4.4 Diagnosing Drug-Resistant Tuberculosis
A major impact of the scale-up of Xpert MTB/RIF is increased detection of RIF
resistance, which is a surrogate marker for MDR TB. Classical diagnosis of drug
resistance in M. tuberculosis involves culture of the bacilli on solid or liquid media
and comparison of growth between drug-free and drug containing media. Even with
the advent of direct liquid culture methodology, detection of drug resistance takes
over two weeks, and with indirect methods, two months or more. Standardisation of
drug susceptibility testing for the antituberculous drugs is difficult and should be
performed in a biosafety level 3 laboratory by trained personnel participating in an
external quality assurance scheme. Isoniazid, rifampicin and streptomycin are the
most reliable drug susceptibility tests.
Molecular detection of drug resistance mutations provides a rapid alternative, but
the accuracy of these tests varies according to the drug. Rifampicin resistance
detection is the most accurate, as 95 % of phenotypically rifampicin resistant strains
carry a mutation in the 81 base pair rifampicin—resistance-determining-region
(RRDR) of the rpoB gene. For isoniazid, molecular methods can detect approxi-
mately 75 % of phenotypically resistant strains by detecting mutations in the katG
gene or InhA promoter region. Development of commercial NAAT for the other
antituberculous drugs has been hampered by incomplete understanding of the
molecular mechanisms of resistance. The principal commercial NAAT for drug
resistance are the Xpert MTB/RIF test and the line probe assays. The most recent
pooled estimates for M. tuberculosis detection by Xpert MTB/RIF were sensitivity
of 88 % (95 %CI; 83–92%) and specificity of 98 % (95 %CI; 97–99 %); for
rifampicin resistance sensitivity 94 % (95 %CI; 87–97 %) and specificity 98 %
(95 %CI; 97–99 %) (Steingart et al. 2014). Line Probe assays detect both rifampicin
and isoniazid resistance simultaneously and the MTBDR-sl assay detects resistance
to fluoroquinolones, ethambutol and aminoglycosides. The MTBDR-sl test has high
sensitivity for fluoroquinolones, but low sensitivity for aminoglycoside and eth-
ambutol resistance (Feng et al. 2013). However, specificity is high for all drugs and
therefore the test can be used to detect resistance but should not be used to rule-out
resistance. Unfortunately, the need remains to confirm susceptibility by laborious
phenotypic DST. Rapid sequencing techniques provide more comprehensive drug
susceptibility data but are not yet widely available beyond research settings.
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Several non-commercial phenotypic DST approaches have been developed
including microscopic observation drug susceptibility testing (MODS), nitrate
reductase assay (NRA) and colorimetric redox indicator (CRI) tests. A MODS test
kit is now available to improve standardization (Hardy diagnostics). In 2010 WHO
issued a recommendation that MODS could be used as an ‘interim’ approach for
increased DST in high-burden countries but concluded that there was insufficient
data to recommend NRA or CRI. Reservations particularly around biosafety and
quality control have limited scale-up of the techniques (Image 4.1).
4.5 Other Diagnostic Methods
In 2011 WHO issued an unprecedented negative advisory on the use of serodiag-
nostic tests for TB (Steingart et al. 2011). These tests are appealing because of they
are simple, rapid, inexpensive and non-invasive and are marketed with claims of
high sensitivity and specificity. However, systematic evaluation of 19 commercially
available tests using a well-characterised serum bank, and systematic review of all
published studies concluded that none was accurate for use in clinical practice
(Steingart et al. 2011). The search for accurate biomarkers for use in serodiagnostic
tests continue, but has so far yielded little promise. Tests under evaluation by the
Image 4.1 Mycobacterial cording in MODS. Image courtesy of Dr. Dang Thi Minh Ha
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Foundation for Innovative New Diagnostics (FIND; www.finddiagnostics.org)
include the loop-mediated isothermal amplification test (LAMP) assay, mobile
NAAT devices, volatile organic compound (VOC) or ‘electronic nose’ tests, an
adapted interferon-gamma release assay, and enzymatic detection systems. It is
unlikely that a true point-of-care test for TB will be available in the next 2–3 years
given the current pipeline of diagnostic tests under evaluation (Thwaites et al. 2003;
UNITAID 2014) (Fig. 4.2).
4.6 Diagnosing Latent Tuberculosis Infection
The interferon gamma release assays (IGRA) were developed as an alternative to
the tuberculin skin test which is confounded by BCG vaccination. Two commercial
IGRAs are currently FDA approved for the diagnosis of M. tuberculosis infection:
The QuantiFERON-TB Gold In-Tube test (QFT-GIT) (Cellestis Limited, Carnegie,
Victoria, Australia, approved 2007); T-Spot test (Oxford Immunotec Limited,
Abingdon, United Kingdom, approved 2008). Whole blood or Peripheral blood
mononuclear cells (PBMC) are stimulated with antigens from M. tuberculosis and
the interferon gamma release stimulated is measured. IGRA which use ESAT-6 and
Fig. 4.2 Current FIND TB diagnostics pipeline listing the development phases and the types of
technologies in development or evaluation, from UNITAID diagnostic technology and market
landscape, 2014, reprinted with permission
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CFP-10 antigens for stimulation are not confounded by prior BCG vaccination
because these antigens are found in a region (RD1) of the M. tuberculosis genome
which is deleted from BCG and thought to be partially responsible for the loss of
virulence.
In the United States, IGRA are widely used for the diagnosis of latent TB
infection and are recommended by CDC guidelines (available at: http://www.cdc.
gov/mmwr/pdf/rr/rr5905.pdf). WHO do not recommend the use of IGRA in
endemic settings or for the diagnosis of active TB. It should be noted that 95 % of
IGRA positive individuals do not go on to develop active TB and therefore the
predictive value of a positive IGRA is extremely low; no statistically significant
difference in the incidence of active TB between IGRA positive and IGRA negative
individuals has been demonstrated in the small number of studies which have
addressed this question.
Open Access This chapter is distributed under the terms of the Creative Commons Attribution
Noncommercial License, which permits any noncommercial use, distribution, and reproduction in
any medium, provided the original author(s) and source are credited.
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Chapter 5
Treatment
Abstract In this chapter the treatment of drug sensitive and drug resistant TB and
timing of antiretroviral treatment for HIV infected patients will be reviewed.
Emphasis is placed on results of recent trials of fluoroquinolones for treatment
shortening of drug sensitive TB. The use of two relatively novel agents in MDR-TB
treatment, bedaquiline and delamanid, will be discussed.
Keywords First-line antituberculous treatment  Rifampicin  Isoniazid 
Pyrazinamide  Streptomycin  Ethambutol  HIV associated tuberculosis 
Antiretroviral therapy (ARV, ART)  Treatment of drug-resistant tuberculosis 
Fluoroquinolones  Bedaquiline  Delamanid
5.1 First-Line Antituberculous Treatment
The introduction of rifampicin to the first-line combination regimen in the late
1970s allowed the shortening of treatment for TB from 18–24 months to 6 months.
This “short-course” regimen, consists of an ‘intensive phase’ of 4 first line drugs;
ethambutol (EMB) [or streptomycin (SM)], isoniazid (INH), pyrazinamide (PZA)
and rifampicin (RIF) for 2 months followed by a ‘continuation phase’ of 2 months
of RIF and INH (Table 5.1). The continuation phase may be extended in more
complex cases and some countries still use an 8-month standard regimen which is
no longer recommended by WHO. Ethambutol should be used in place of the
injectable streptomycin where possible for HIV-infected individuals. Since the
development of the short-course regimen, standard TB-treatment has remained
largely unchanged for the past 40 years. Daily, directly observed therapy (DOT) is
preferable to intermittent regimens and fixed dose combination (FDC) drugs may be
used to ensure multi-drug therapy (Nunn et al. 2014). Pyridoxine should be
administered with isoniazid to prevent peripheral neuropathy. The historic events
that have led to the current treatment schedule are comprehensively reviewed by
Diacon and colleagues (Diacon et al. 2012).
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WHO treatment guidelines can be found at http://www.who.int/tb/publications/
tb_treatmentguidelines/en/index.html. Treatment recommendations for pediatric TB
were revised in 2010, with an increased dose of all first-line drugs (http://
whqlibdoc.who.int/publications/2010/9789241500449_eng.pdf) and a request not











Group 5: Agents with unclear role in treatment of drug resistant-TBc
























16–20 mg/kg/day Hepatitis; peripheral
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Delaminid 200 mg twice
daily
QT prolongation
aHypersensitivity reactions and drug rashes may occur with any anti-tuberculous drug
bPyridoxine should be given with isoniazid to prevent peripheral neuropathy. Guidelines variously
recommend 10 or 25 mg/kg daily
cOptimal dose and long-term safety not well established for group 5 drugs
dDo not use thioazetone for HIV-infected individuals (significant risk of Stevens-Johnson
syndrome)
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2014). This followed systematic review of evidence showing that children achieve
inadequate serum exposure when receiving the same dose/kg as adults and there
was no evidence of adverse toxicity from the higher doses. Pharmacokinetic data
from South Africa showed substantially improved serum levels with the novel
regimen but it remains to be demonstrated if these doses are sufficient to achieve
improved outcomes (Thee et al. 2011).
5.2 HIV Associated Tuberculosis
The advent of HIV has severely impacted the burden of TB. All HIV patients
should be screened for TB and all TB patients should be offered HIV testing. Dual
treatment of HIV and TB is complex, as patients are faced with a higher pill-burden,
increased risk of toxicity, drug-interactions and IRIS (Lawn et al. 2013; Lai et al.
2013). Routine administration of co-trimoxazole (960 mg/day) is recommended in
all patients with HIV-associated TB, since it has been shown to substantially reduce
mortality in patients in Sub Saharan Africa. Rifampicin is an inducer of the cyto-
chrome P450 2B6 enzyme, which is the main pathway for the non-nucleaside
reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs) either of
which are the basis of ARV treatment (Bonnet et al. 2013). The most commonly
used NNRTI is efavirenz. Although the US FDA recommends that the dose of
efavirenz should be increased when co-administered with rifampicin, this is not
substantiated in the most recent clinical trials, which show excellent virological
response in those patients receiving standard dose (600 mg) of efavirenz (Kwara
et al. 2010). Nevarapine is an alternative NNRTI used for those patients who cannot
tolerate efavirenz, but plasma levels are very low in patients receiving rifampicin
during the lead-in phase of nevarapine. This may predispose to resistance formation
and virological failure. Dose increase is not recommended because concerns of
toxicity, however it is plausible to omit the 14 day lead-in phase of nevirapine
dosing after the CARENIMO trial showed that nevirapine was well tolerated at full
dose when introduced in patients with CD4 cell counts <250/mm3 while receiving
rifampicin (Bonnet et al. 2013). The co-administration of second-line ARV regi-
mens containing PIs remains a challenge and there is an urgent need for clinical
trials evaluating safety and efficacy. ‘Superboosting’ of ritonavir or doubling dose
of lopinavir/ritanovir combination formulation are suggested, as is substituting ri-
fabutin for rifampicin (Lawn et al. 2013).
Timing of initiation of ARV treatment in ARV-naïve TB/HIV patients has been
evaluated in a recent series of clinical trials published in 2011 (SAPIT
[NCT00398996], CAMELIA[NCT01300481] and the AIDS clinical trial group
study A5221). Results showed that there is a reduction in mortality in patients with
CD4 cell counts lower that 200/mm3 (CAMELIA trial) or 50/mm3 (other two trials)
when ARV treatment was initiated within 2 weeks of TB treatment (GRADE A3),
(Abdool Karim et al. 2010, 2013; Blanc et al. 2011). However this carries an
increased risk of IRIS and treatment toxicity. The management in patients with
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higher CD4 cell counts is less clear and it may be acceptable to defer ARV treat-
ment until the continuation phase of TB treatment. The majority of patients in these
trials had pulmonary TB. For patients with TB meningitis, a recent large
Vietnamese randomised controlled trial showed no benefit of early initiation of
ARVs and deferred treatment at 2 months was associated with less toxicity and less
occurrence of IRIS (Torok et al. 2011). Patients in this cohort had extremely low
median CD4 count and the results may not be generalizable to other populations.
5.3 Treatment of Drug-Resistant Tuberculosis
The use of multi-drug therapy for TB treatment from the early days of discovery of
antituberculous drugs has actually preserved the efficacy of the five first line agents for
TB remarkably well for over 50 years. However, drug resistance inM. tuberculosis is
increasing and has now reached alarming levels, particularly in the former Soviet
states, India, South Africa and part of Asia. Approximately 8 % of M. tuberculosis
cases globally are now resistant to isoniazid. Multi-drug resistant TB (MDR TB) is
defined as TB resistant to at least isoniazid and rifampicin, the two key first line drugs
in the treatment regimen. MDR TB is much harder to treat, requiring a minimum of
18 months treatment with expensive, toxic and weak second line drugs. Worldwide,
3.6 % of newly diagnosed and 20 % of patients previously treated for TB have
MDR TB but there are dramatic regional variations with the highest proportion in
Eastern Europe and Central Asia (WHO 2014).
In 2012 there were an estimated 450,000 new cases of MDR TB worldwide and
170,000 deaths but only 17 % were diagnosed and enrolled into high quality
treatment programmes. This figure does however represent a 42 % increase on
2011, reflecting scale-up efforts for MDR detection and treatment. In 2006 WHO
defined a new category of drug resistant TB as extensively drug resistant TB (XDR
TB). XDR TB is MDR TB additionally resistant to a fluoroquinolone and a second
line injectable drug (amikacin, capreomycin or kanmycin). This followed a docu-
mented outbreak in Kwa-Zulu Natal province of South Africa in which 53 cases of
XDR TB were identified among HIV patients, all but one of whom died with a
median survival time of 16 days from diagnosis. Following acceptance of the
definition of XDR TB, 92 countries have reported cases by 2013 (Fig. 5.1). It is
estimated 10 % of MDR cases are in fact XDR and it is now clear that XDR TB is
present in almost every country although the extent of transmission within com-
munities is not established due to the limited availability of second-line drug sus-
ceptibility testing for M. tuberculosis. The term totally drug resistant TB has been
used in the literature to describe M. tuberculosis strains resistant to all first and
second line drugs but the use of this term is not recognised by WHO due to the
difficulty of standardising drug susceptibility testing for second line drugs and the
introduction of treatment options (Cegielski et al. 2012).
Drug resistant TB should be treated with at least four drugs to which the
organism is susceptible, prioritising any first-line agents and then including a
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fluoroquinolone and an injectable agent. In order to protect against drug resistance
amplification, a single drug should never be added to a failing regimen (Daley and
Caminero 2013). Key principles of MDR treatment are summarised in Table 5.2
(Kaufmann et al. 2014; Ulrich et al. 2006).
Comprehensive CDC guidelines on both susceptible and drug resistant TB can
be found on http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm.
The painstakingly sluggish decline in incidence of TB and the rise of MDR- and
XDR-TB underlines the inadequacies of current treatment and prevention measures.
Priority questions for research, in addition to the search for novel agents include
shortened regimens, optimal regimens for all forms of drug resistant TB, optimal
dose of drugs (especially rifampicin), and treatment of HIV-associated TB.
Several existing and newly developed compounds are under evaluation for drug-
sensitive and drug-resistant TB (Fig. 5.2). In light of the growing epidemic of
MDR-TB and lack of new drug development there has been renewed interest in
obsolete compounds for TB (Chang et al. 2013). In 2010, the Damien Foundation
published the results of an observational study, comparing six regimens for
MDR-TB, derived by sequential modification. The addition of gatifloxacin and use
of clofozimine throughout the regimen apparently allowed a reduced duration of
treatment, to between 9–12 months, depending on time to smear conversion. All
427 patients received clofazimine in the intensive phase and 206 patients received a
shortened regimen of 9–12 months, using clofazimine throughout treatment [4(+)
KCGEHZP, 5 GCEZ]. Treatment success-rate was highest in the short regimen
Fig. 5.1 Percentage of previously treated TB cases with multidrug-resistant TB. Source WHO,
reprinted with permission
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treatment group with a relapse-free cure of 87.9 % (95 %CI 82.7–91.6), with
relatively good tolerability (Van Deun et al. 2010). This shortened ‘Bangladesh’
regimen is now being subjected to a large multicentre (including sites in Ethiopia,
India, South Africa, Vietnam) randomised controlled trial, known as the STREAM
trial (ISRCTN78372190). The STREAM trial is being conducted by the British
Medical Research Council and will compare the standard MDR regimen (according
to local National TB program guidelines, duration ranging from 18–24 months)
with a modified form of the Bangladesh regimen. Moxifloxacin, clofazimine, eth-
ambutol and pyrazinamide will be given for nine months, supplemented by kana-
mycin, isoniazid and prothionamide in the four months of the intensive phase. All
drugs are given daily except for kanamycin which is administered thrice weekly
after 12 weeks. The target is to include at least 400 participants. The results of this
major trial are expected in October 2016.




Do not add a single drug to a failing regimen
When starting or modifying therapy, add three previously
unused drugs (one an injectable) to which there is likely to be
susceptibility
Use any of the first-line oral agents (Group 1) that are likely to
be effective
In multidrug-resistant tuberculosis (MDR TB), when there is
resistance to additional first-line drugs, treat with 4–7 drugs
(dependent on degree of confidence in susceptibility and
strength of derived regimen)
Patients with MDR TB have the highest priority for directly
observed therapy because treatment failure may be associated
with extensively drug-resistant TB
Intermittent therapy should not be used (except for injectables
after 2–3 months)
Do not use drugs to which the M. tuberculosis isolate is
resistant. Low-level resistance to isoniazid may be an exception
There is cross-resistance among rifamycins but not between
streptomycin and other aminoglycosides. Amikacin or
kanamycin are preferred aminoglycosides for MDR as most
MDR strains are resistant to streptomycin
Drug susceptibility testing for pyrazinamide is complex
technically and not performed in most laboratories.
Monoresistance to pyrazinamide suggests M. bovis
Drug susceptibility results for second line agents (except
fluoroquinolones and aminoglycosides) may be unreliable and
should be interpreted within context of treatment history
Levofloxacin, or moxifloxacin are preferred flouroquinolones.
Ciprofloxacin should not be used to treat TB
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5.4 The Role of Fluoroquinolones
The fluoroquinolones levofloxacin, gatifloxacin and moxifloxacin have strong an-
timycobarterial activity with an early bactericidal activity (EBA) similar to that of
isoniazid and are the strongest of the second-line agents. Fluoroquinolones are the
keystone of MDR treatment regimens and should also be considered in cases of
non-MDR drug resistant TB requiring additional agents or if a first-line agent in the
standard regimen is not tolerated, particularly in case of hepatotoxicity.
Fluoroquinolones are excreted via the kidneys and thus have a lower potential to
disturb liver function. They inhibit bacterial replication via the DNA gyrase, a
mechanism distinct from those of the first-line agents. They have broad-spectrum
antibacterial activity, particularly against gram-negative bacteria, favourable phar-
macokinetic profile, are relatively safe, have good tissue penetration and high
in vitro activity against M. tuberculosis. Fluoroquinolones may therefore work
synergistically to the other TB agents and penetrate well in the tuberculoma.
A recent Cochrane review, evaluating RCTs on ofloxacin, levofloxacin,
moxifloxacin and gatifloxacin, reported that there is insufficient evidence to be clear
whether fluoroquinolones, either added to the first-line regimen or as a substitution
for ethambutol or isoniazid, may prevent relapse or death, or increase sputum
culture conversion at 8 weeks (Ziganshina et al. 2013). Three large multicountry
trials have been established to determine if the use of fluoroquinolones can shorten
treatment regimens to four months rather than six: OFLOTUB (NCT00216385),
REMOX TB (NCT00864383) and RIFAQUIN (ISRCTN44153044) studies (Merle
et al. 2014; Gillespie et al. 2014; Jindani et al. 2013). The RIFAQUIN trial reported
in April 2013 and showed inferiority of the four month regimen; Two months of
daily ethambutol, moxifloxacin, rifampicin and pyrazinamide followed by two
months of twice weekly moxifloxacin (500 mg) and rifapentine (900 mg) compared
to the standard 6-month WHO regimen (2HRZE/4HR).
The OFLOTUB trial which tested a 4 month regimen of 2 months gatifloxacin
(400 mg/day), isoniazid, rifampicin and pyrazinamide followed by two months
gatifloxacin, isoniazid and rifampicin reported in September 2013 and
(2GHRZ/2GHR) failed to show non-inferiority of the Gatifloxacin regimen at the
pre-specified 6 % margin (Merle et al. 2014). Although Gatifloxacin has been
banned by the FDA due to toxicity concerns, there was no increased risk of dis-
gylcemia or QTc prolongation with the gatifloxacin regimen. The REMOX trial
which tested two moxifloxacin containing regimens lasting 17 weeks, reported in
2014. The moxifloxacin-containing regimens produced a more rapid initial decline
in bacterial load, as compared with the control group. However, noninferiority for
these regimens was not shown, which indicates that shortening treatment to
4 months was not effective in this setting (Gillespie et al. 2014). Several existing
and newly developed compounds are under evaluation for drug- sensitive and
drug-resistant TB (Fig. 5.2) (Ma et al. 2010; Chang et al. 2013; Gopal et al. 2013).
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5.5 Bedaquiline
Bedaquiline (trade name Sirtuto) is a diarylquinoline drug, formerly known under
its code name TMC207, which was discovered in 2005 by Koen Andries and
colleagues in Belgium. It has a novel mode of action, acting by inhibiting ATP
synthase, and is active against replicating and non-replicating bacilli. The first phase
II trial on 47 patients was published in 2009 in the New England Journal of
Medicine and showed that addition of TMC207 to a standard second line regimen
led to a higher proportion of patients with sputum conversion at 8 weeks of
treatment (48 % vs. 9 %), (Diacon et al. 2012). The long-term 2 year follow up
results for this pilot trial were published in 2012 and showed a significant reduction
in time to sputum conversion in the TMC207 patients compared to placebo and less
acquisition of resistance to companion drugs in the TMC207 group, however this
did not reach statistical significance. With the exception of nausea, which was more
frequently reported in the TMC207 patients, the occurrence of adverse events was
not different between the two groups (Diacon et al. 2014). These results combined
with two other phase II trials have led to accelerated approval of the drug by the
FDA in 2012. This was the first new TB drug added to the arsenal of agents in
decades. FDA approval was conditional upon prioritisation of phase three trials, but
these have not yet started. The WHO and CDC have published provisional
guidelines on the use of bedaquiline: http://www.who.int/tb/challenges/mdr/
bedaquiline/en/index.html and http://www.cdc.gov/mmwr/preview/mmwrhtml/
rr6209a1.htm?s_cid=rr6209a1_e (Provisional CDC guidelines for the use and
safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of
multidrug-resistant tuberculosis 2013).
Fig. 5.2 TB drug discovery pipeline
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5.6 Delamanid
Delamanid, (OPC 67683) is a nitro-dihydro-imidazooxazole derivative which acts
by blocking the synthesis of myolic acids, thus interfering with cell-wall integrity of
the mycobacteria. It was first proposed to be a potential new candidate for treatment
of TB in 2006 by Japanese scientists working for Otsuka Pharmaceutical.
Subsequently it has shown promising results in phase IIa and b trials. In a seminal
RCT including 481 patients recruited in 17 centers in 9 countries, the proportion of
sputum positive MDR-TB patients that converted to sputum negative after 2 months
of treatment with delamanid (100 mg BID) added to an optimised background
regimen (n = 161) was 45.4 % opposed 29.6 % in those patients receiving a
background regimen and placebo (n = 160) (p = 0.008). The patients receiving
delamanid had significantly shorter time to sputum negativity and, additionally, a
mortality benefit was observed for those in the active arms of this trial (Gler et al.
2012). Phase III trials are underway.
The European Medicines Agency (EMA) approved the drug for use in MDR-TB
in November 2013, making Delamanid the second drug to be approved for use in
(MDR-)TB in 50 years. It will be manufactured under the name of Deltyba.
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Abstract Prevention is the key to stop transmission of TB. It consists of early
diagnosis and treatment of active TB to stop infectiousness, the prevention of active
disease in exposed or known latently infected individuals and vaccination.
Vaccination with the Bacillus Calmette-Guerin (BCG) vaccine is unfortunately
largely ineffective in interrupting transmission. However a more powerful vaccine
will have the potential to cause a major shift in the management of TB. In this
chapter prophylactic treatment in latently infected and HIV infected patients is
reviewed. Additionally the prevention of active disease in MDR-exposed persons
and vaccine development will be discussed.
Keywords Prophylactic treatment  Prophylactic treatment in multi-drug resistant
tuberculosis  Vaccine  Latent tuberculosis  Prevention
6.1 Prophylactic Treatment
TB transmission to susceptible contacts primarily occurs in enclosed, poorly ven-
tilated locations. High risk locations for transmission are high density congregate
living environments such as hospitals, care homes, prisons or student/migrant
worker hostels. Transmission within institutional environments such as hospitals
can be reduced by implementing effective infection control policies covering
administrative, environmental and respiratory protection (refer to CDC guidelines
for detailed recommendations: http://www.cdc.gov/tb/publications/guidelines/
infectioncontrol.htm).
The standard regimen for treatment of latent TB infection is nine months iso-
niazid, also known as isoniazid prophylaxis therapy (IPT). Pyrodoxine should be
given with isoniazid (Udani et al. 1971). In 2011 a trial of a novel 12 dose regimen
of isoniazid and rifapentine showed higher completion rates and no loss of efficacy
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compared to the standard 9-month isoniazid treatment (Sterling et al. 2011). The
12-dose regimen has since been incorporated into US recommendations but is not
recommended for children younger than 2 years of age, people with HIV/AIDS
who are taking antiretroviral therapy (ART), people presumed to be infected with
INH or rifampin-resistant M. tuberculosis or pregnant women, or women expecting
to become pregnant while taking this regimen: http://www.cdc.gov/tb/publications/
ltbi/treatment.htm.
A recent mass isoniazid prevention trial in South African mine workers showed
no reduction in TB incidence and prevalence beyond the 9 months of IPT, sug-
gesting that in high TB burden areas, transmission is not interrupted and the
unchanged incidence is due to reinfection (Churchyard et al. 2014).
HIV is the strongest risk factor for developing TB in those with latent or recent
M. tuberculosis infection, between 20 and 37 times the risk for those without HIV.
To avoid treating an active TB case with monotherapy, HIV-infected individuals
should be screened for active TB before the administration of IPT (Rangaka et al.
2014).
There is considerable debate around the duration of IPT in HIV-infected indi-
viduals since the trial data from South African miners who are heavily exposed
showed that the protective effect of IPT quickly wanes, with the protective effect
disappearing after one year. This is likely to be due to IPT clearing any latent infection,
and therefore preventing reactivation disease, but not preventing re-infection after
completion of therapy. WHO recommends extended IPT (36 months) for individuals
living in areas with a high background prevalence of HIV and TB. There is concern
that the widescale application of long-term IPT will lead to increases in isoniazid
resistance and decrease in efficacy over time, but there is no evidence that this is
occurring. Trials of long-term IPT are now underway in South Africa.
The reservoir of latently infected individuals is clearly a major barrier to eventual
TB elimination, and shorter, less toxic regimens for latent TB will be a major boost
to elimination efforts.
For more information on TB prevention: http://www.tbfacts.org/tb-prevention.
html.
6.2 Prophylactic Treatment in Multi-drug Resistant
Tuberculosis
Evidence to guide the choice of regimen for prophylatic treatment of the contacts of
MDR and XDR TB patients is extremely limited. Derivation and testing of
standardised regimens is complicated by the diverse spectrum of possible suscep-
tibility patterns of an index case.
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The American Thoracic Society (ATS) and the US Centers for Disease Control
and Prevention (CDC) recommend prophylactic therapy for MDR TB contacts with
the regimen to be used determined by the drug susceptibility profile of the potential
source case. WHO and European guidelines [The International Standards for TB
Care (ISTC) and European Union Standards for TB Care (ESTC)] favour careful
clinical follow-up for a period of at least two years.
The European Centre for Disease prevention and control issued guidance on
management of contacts of MDR and XDR patients in 2012 based upon systematic
review of the available evidence: http://www.ecdc.europa.eu/en/publications/
publications/201203-guidance-mdr-tb-contacts.pdf. The guidance recommends
that each case must be considered individually with a comprehensive assessment of
the likely risks and benefits of preventative therapy of unknown efficacy versus
intensive clinical monitoring for signs of disease. The risk assessment should
include consideration of any known individual risk factors for progression to active
disease, the drug susceptibility pattern of the index case and any known risk factors
for adverse events with the prophylactic regimen. A recent prospective observa-
tional study on an island in Micronesia, followed MDR-TB contacts who were
offered 12-month preventive treatment with a fluoroquinolone. Among the 119
infected contacts, 15 refused, while 104 began treatment for MDR latent TB
infection. None of the 104 contacts who undertook treatment with fluoroquinolones
developed MDR-TB disease; however, 3 of 15 contacts who refused and 15
unidentified contacts developed MDR-TB disease (Bamrah et al. 2014). These data
are compelling and warrant randomized studies, as the ability to prevent MDR-TB
transmission would be the paradigm shift in MDR-TB management.
6.3 Vaccines
The only vaccine currently available for TB is the bacillus Calmette-Guerin
(BCG) vaccine developed by serial passage ofMycobacterium bovis and introduced
in 1921. BCG is the most widely used vaccine in the world but measures of
effectiveness have varied widely, between 0 and 80 %. Studies have however,
consistently shown a protective effect against the most severe forms of childhood
TB, including TB meningitis. Meta-analysis of all published studies produced an
estimate of 50 % for overall efficacy and 80 % efficacy in preventing TB meningitis
(Colditz et al. 1994). BCG should not be administered to HIV-infected individuals
(Nuttall and Eley 2011). Several theories have been proposed for the differences in
observed effectiveness, including the use of different strains of BCG, variation in
early exposure to non-tuberculous mycobacteria prior to vaccination, host genetic
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variation and pathogen genetic variation but none of these theories has strong
supporting evidence to date.
Clearly, given the huge burden of global TB and the major barrier to elimination
that the ‘silent’ reservoir of latently infected individuals represents, an effective TB
vaccine would be a major advance in the battle to eradicate TB. However, the
correlates of protective immunity in TB are not understood which represents a
major hurdle to developing an effective vaccine. The most advanced vaccine can-
didate for a primary TB vaccine, MVA85A, failed to show any efficacy in a phase
IIb trial in HIV-uninfected infants published in 2013 (Tameris et al. 2013). This trial
should however provide valuable data to guide further development of novel
vaccine candidates.
The current pipeline includes three distinct approaches to the development of a
TB vaccine, known as Prime, boost or immunotherapy. An alternative strategy also
being explored is post-infection vaccination. Vaccine types currently
under-development include (1) modification of the BCG vaccine (recombinant
BCG), (2) Boosting of BCG with adjuvants, (3) incorporation of TB antigen
expression into vaccine vectors or (4) killed whole cell or extracts (Kaufmann et al.
2014).
6.4 Concluding Remarks
TB is a curable disease. The fact that it remains the most pressing public health
problem for a significant proportion of the world, despite the availability of a cure
and knowledge on prevention of transmission shows how medicine can fail without
commitment at all levels of the community. The distribution of the TB pandemic
painfully demonstrates the inequalities in health care delivery globally. Over 95 %
of cases and deaths are in low and middle income countries. In general, prognosis
of outcome is dependent on a multitude of factors: host factors (genetic variance,
co-morbidities, HIV-coinfection, treatment adherence, access to healthcare) and
pathogen factors (pathogen virulence, drug-resistance) and the site of the infection
(pulmonary or extrapulmonary). The principle factor in a favourable outcome for all
forms is early recognition and appropriate treatment. TB is the most common cause
of death among HIV patients, estimated to cause a quarter of AIDS related deaths.
Drug resistant TB is a growing problem and threatens to reverse the recent gains
in global TB control. In regions of the former soviet states MDR TB is found in over
half of all new TB cases and threatens a return to untreatable strains of TB dis-
seminating globally without immediate and sustained action. Of the 34,000 MDR
patients enrolled on treatment in 2010, only 48 % successfully completed treatment
and 15 % died. Among 795 XDR cases, mortality was approximately 50 %.
The key to maintaining the momentum towards achieving the STOPTB target of
global TB eradication by 2050 will be sustained commitment from donors, gov-
ernments, national TB programmes, researchers and other stakeholders at all levels
of society.
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